ClinicalTrials.gg
CompletedNCT05208151Updated Jun 16, 2022

Creative Drama in Physiotherapy and Rehabilitation Education

An interventional study of Creative Drama Education in Educational Problems, sponsored by Acibadem University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-16.

Sponsored by Acibadem University · Not applicable, Interventional, and Screening

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Sep 2021, registered Dec 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 25 Years
Sex
All
01

Study summary

Candidates who will provide the health services of the future should be ready to provide the safe and best health care services. In order to achieve this, it is recommended to use new training programs and methods that will provide similar situations to the working environment in the training of health workers. There are very few studies on the empathy and communication perceptions that creative drama education will create with the patient on physiotherapy and rehabilitation department students. Therefore, this study, the investigators aimed to investigate the perceived effect of communication skills training integrated with creative drama on physiotherapy and rehabilitation students' empathy and communication skills that will develop with the patient.

02

Conditions studied

  • Educational Problems

Keywords

  • Education
03

In context

Lead sponsor

Acibadem University is the lead sponsor of 218 studies on the registry; 49 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being willing to take FZT 233 Effective Communication with Creative Drama in Health course in any of the fall or spring semesters.

Exclusion criteria

Exclusion Criteria:

  • Desire to take FZT 233 Effective Communication with Creative Drama in Health course at his own request.

    • Not wanting to participate in the study
    • Having a diagnosed psychological disorder and/or receiving psychological treatment
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    Creative Drama Group

    Other: Creative Drama Education

  • No intervention
    Control Group

Interventions

  • OtherCreative Drama Education

    Effective Communication with Creative Drama in Health Course will be given to students for 2 hours a week for 14 weeks.

06

What researchers measure

Primary outcomes

  1. interpersonal communication questionnaire

    It is stated that the first four items are related to communication anxiety and the last four items are related to communication trust. Each item has a 5-point Likert scale between 1 = strongly disagree 5 = strongly agree. High values indicate poor communication

    Time frame: Change from Baseline interpersonal communication questionnaire at 14 weeks

  2. Jefferson Doctor Empathy Scale

    The score range is 20-140, with higher average scores representing higher levels of empathy.

    Time frame: Change from Baseline Jefferson Doctor Empathy Scale at 14 weeks

Secondary outcomes

  1. Visual analog scale-communication

    A visual analog scale between 0 and 10 will be used to evaluate the communication that may occur when students go into clinical practice at the beginning and end of the term and when they meet the patient. Zero will be set to none, 10 will be set to the maximum I can think of.

    Time frame: Change from Baseline Visual analog scale at 14 weeks

  2. Visual analog scale-anxiety/stress

    A visual analog scale between 0 and 10 will be used to evaluate the anxiety/stress that may occur when students go into clinical practice at the beginning and end of the term and when they meet the patient. Zero will be set to none, 10 will be set to the maximum I can think of.

    Time frame: Change from Baseline Visual analog scale at 14 weeks

  3. Visual analog scale-motivation

    A visual analog scale between 0 and 10 will be used to evaluate the motivation that may occur when students go into clinical practice at the beginning and end of the term and when they meet the patient. Zero will be set to none, 10 will be set to the maximum I can think of.

    Time frame: Change from Baseline Visual analog scale at 14 weeks

07

Study locations

1 site
  • Acıbadem University
    Istanbul, +90, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Jan 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2021
First posted
Jan 26, 2022
StartActual
Sep 16, 2021
Primary completionActual
Jan 15, 2022
CompletionActual
Feb 15, 2022
Last update
Jun 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05208151
Responsible party
Nuray Alaca (Assoc Prof. Nuray Alaca, Acibadem University) — Principal investigator
First posted
Jan 26, 2022
Start date
Sep 16, 2021
Primary completion
Jan 15, 2022
Completion
Feb 15, 2022
Last update
Jun 16, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion